Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Brokerages

Key Points

• Astria Therapeutics, Inc. has received an average rating of "Buy" from seven brokerages, with an average target price of $30.20.
• The company's most recent earnings report showed an EPS of (0.57), surpassing estimates, while analysts predict an average EPS of (1.65) for the current fiscal year.
• Institutional investors own 98.98% of Astria Therapeutics' stock, indicating strong market confidence and investment in the company.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given an average rating of "Buy" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $30.20.

Several research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $49.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, September 17th. JMP Securities raised their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 13th. HC Wainwright lifted their price target on shares of Astria Therapeutics from $16.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, September 17th. Finally, Citigroup reiterated an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th.

Astria Therapeutics Stock Performance

Shares of ATXS stock traded down $0.03 during mid-day trading on Friday, reaching $7.49. 46,598 shares of the company's stock traded hands, compared to its average volume of 362,497. The firm has a market capitalization of $422.45 million, a PE ratio of -3.74 and a beta of 0.42. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.72. The firm has a 50 day moving average price of $6.79 and a two-hundred day moving average price of $5.76.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.04. As a group, equities analysts expect that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in Astria Therapeutics by 4,607.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company's stock valued at $9,091,000 after purchasing an additional 1,660,039 shares during the period. ADAR1 Capital Management LLC grew its stake in shares of Astria Therapeutics by 605.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock worth $3,427,000 after buying an additional 550,706 shares in the last quarter. Nantahala Capital Management LLC increased its stake in Astria Therapeutics by 59.7% during the second quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company's stock worth $5,733,000 after acquiring an additional 400,000 shares during the last quarter. Vestal Point Capital LP raised its holdings in Astria Therapeutics by 8.2% during the 2nd quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock valued at $24,238,000 after buying an additional 342,000 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Astria Therapeutics in the second quarter valued at $1,608,000. Hedge funds and other institutional investors own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.